Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|169|2|219-227

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.169, Iss.2, 2015-04, pp. : 219-227

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 6, 2015-09 ,pp. : 804-813

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 1, 2015-04 ,pp. : 36-43

John Wiley & Sons Inc

Access to resources Recommend Favorite

Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 5, 2015-06 ,pp. : 754-756

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bortezomib‐thalidomide‐dexamethasone versus bortezomib‐cyclophosphamide‐dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 4, 2015-02 ,pp. : 605-606

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 7-1048, Iss. 1, 2015-10 ,pp. : 52-59

John Wiley & Sons Inc

Access to resources Recommend Favorite